Viral Encephalitis

1. Disease Information

Viral encephalitis is inflammation of the brain parenchyma due to viral infection, presenting as a neurologic emergency with high morbidity and mortality. Key identifiers: - MONDO: MONDO_0006009 ("viral encephalitis") - ICD-10: A85-A89 (various viral encephalitides), A86 for "unspecified viral encephalitis" - MeSH: D004677 ("Encephalitis, Viral") - OMIM: Not a single entry; virus-specific (e.g., OMIM:603705 for HSV-1) - Orphanet: ORPHA:230475 ("viral encephalitis")

Common synonyms: "viral meningoencephalitis", "acute viral encephalitis", "primary viral encephalitis". Information here is derived from aggregated disease-level resources and primary literature.

2. Etiology

Viral encephalitis is caused by neurotropic viruses. Principal viral agents include: | Virus family | Virus | Typical transmission route | Geographic distribution / epidemiology | Case fatality rate / severity notes | |---|---|---|---|---| | Herpesviridae | HSV-1 | Reactivation or primary infection with neural spread to CNS; trans-synaptic spread from trigeminal/olfactory pathways | Worldwide; leading cause of sporadic, non-epidemic encephalitis in developed settings; HSV accounts for >90% of encephalitis cases among immunocompetent adults in HSV encephalitis series (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 2-3, cleaver2024theimmunobiologyof pages 3-4) | Untreated HSE mortality historically ~70%; with aciclovir, mortality falls to ~10–25%; long-term neurologic disability remains common (cleaver2024theimmunobiologyof pages 2-2) | | Herpesviridae | HSV-2 | Perinatal/neonatal transmission most important for encephalitic disease; less commonly adult CNS infection | Worldwide; causes ~80% of neonatal HSV CNS cases in cited review (yang2023advancesinviral pages 2-3) | Specific CFR not consistently separated from HSV-1 in retrieved evidence; neonatal disease can be severe and life-threatening (yang2023advancesinviral pages 2-3) | | Flaviviridae | Japanese encephalitis virus (JEV) | Mosquito-borne | Endemic in Southeast Asia and the Western Pacific; most common epidemic viral encephalitis globally; ~68,000 cases annually, with ~1.15 billion people at risk (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 1-2) | Review evidence notes 10,000–15,000 deaths annually; severe neurologic sequelae common among survivors (yang2023advancesinviral pages 1-2) | | Flaviviridae | West Nile virus (WNV) | Mosquito-borne | Africa, Europe, Middle East, North America, West Asia; important cause of arboviral neuroinvasive disease, including in Europe (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | In retrieved evidence, exact CFR for encephalitis not consistently quantified; recognized cause of severe neuroinvasive disease with substantial morbidity (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | | Flaviviridae | Tick-borne encephalitis virus (TBEV) | Ixodes tick bite; less often alimentary transmission via unpasteurized dairy | Focally endemic in Europe and Asia; ~5,000–10,000 human cases annually in endemic areas; highest incidence in older adults, male predominance (hills2023tickborneencephalitisvaccine pages 5-6) | Mortality varies by subtype; severe disease risk higher in age ≥60, immunocompromise, and Far Eastern subtype infection; often causes permanent neurologic/cognitive sequelae (hills2023tickborneencephalitisvaccine pages 5-6) | | Flaviviridae | Zika virus (ZIKV) | Primarily mosquito-borne; also sexual, vertical, and transfusion routes recognized broadly | Tropics/subtropics with outbreaks in the Americas, Pacific, Asia, and Africa; included among major neurotropic RNA viruses causing VE (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | Exact encephalitis CFR not established in retrieved evidence; neurologic disease recognized but encephalitis less common than congenital/CNS developmental complications (yang2023advancesinviral pages 1-2) | | Flaviviridae | Dengue virus (DENV) | Mosquito-borne | Global tropical/subtropical distribution; increasing autochthonous transmission in Europe noted in recent review (yang2023advancesinviral pages 1-2) | Exact encephalitis CFR not given in retrieved evidence; dengue can be neuropathogenic and contribute to VE burden (yang2023advancesinviral pages 1-2) | | Togaviridae / Alphavirus | Eastern equine encephalitis virus (EEEV) | Mosquito-borne; laboratory aerosol exposure also documented | Primarily eastern North America; average ~11 annual human cases, but outbreaks occur (woodson2025neuropathogenesisofencephalitic pages 6-8) | High CFR ~30–75%; among survivors, 50–90% experience neurologic sequelae (woodson2025neuropathogenesisofencephalitic pages 6-8, woodson2025neuropathogenesisofencephalitic pages 3-4) | | Togaviridae / Alphavirus | Venezuelan equine encephalitis virus (VEEV) | Mosquito-borne; aerosol exposure possible in laboratory/biothreat settings | Americas; causes epizootic and enzootic disease in humans and equids (woodson2025neuropathogenesisofencephalitic pages 3-4, woodson2025neuropathogenesisofencephalitic pages 1-3) | Overall mortality usually <1%, but can reach ~10% in adults with neurologic disease and ~35% in children in cited review (woodson2025neuropathogenesisofencephalitic pages 3-4) | | Togaviridae / Alphavirus | Western equine encephalitis virus (WEEV) | Mosquito-borne | Historically Americas, especially western North America (woodson2025neuropathogenesisofencephalitic pages 3-4, woodson2025neuropathogenesisofencephalitic pages 1-3) | CFR ~3–15%; neurologic sequelae common in survivors (woodson2025neuropathogenesisofencephalitic pages 3-4) | | Rhabdoviridae | Rabies virus | Animal bite with saliva inoculation; neuronal spread to CNS | Worldwide, especially Asia and Africa; classic neurotropic encephalitic virus included among major VE causes (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | Once clinical encephalitis develops, rabies is typically nearly uniformly fatal; exact figure not quantified in retrieved evidence (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | | Picornaviridae | Enteroviruses (e.g., EV71) | Fecal-oral, respiratory, close contact | Worldwide, especially pediatric populations in Asia-Pacific outbreaks; important cause of viral CNS infection (yang2023advancesinviral pages 1-2, yang2023advancesinviral pages 2-3) | Exact CFR for encephalitis not consistently reported in retrieved evidence; can cause severe pediatric brainstem encephalitis and neurologic complications (yang2023advancesinviral pages 2-3) | | Coronaviridae | SARS-CoV-2 | Respiratory transmission | Worldwide pandemic distribution; included among major RNA viruses associated with VE and post-infectious CNS syndromes (yang2023advancesinviral pages 1-2, loscher2022molecularmechanismsin pages 1-2) | Exact CFR for encephalitis not established in retrieved evidence; neurologic involvement recognized but heterogeneous (yang2023advancesinviral pages 1-2, loscher2022molecularmechanismsin pages 1-2) | | Paramyxoviridae | Measles virus | Respiratory droplets / airborne | Worldwide where vaccination gaps persist; included among viral encephalitis pathogens and also relevant to post-vaccine susceptibility syndromes in interferon-pathway deficiencies (yang2023advancesinviral pages 1-2, OpenTargets Search: viral encephalitis,encephalitis) | Exact encephalitis CFR not quantified in retrieved evidence; measles encephalitis can be severe/fatal (yang2023advancesinviral pages 1-2) | | Orthomyxoviridae / Pneumoviridae and others | Respiratory viruses with encephalitic complications (e.g., RSV, influenza) | Respiratory transmission | Worldwide; RSV meta-analysis found encephalitis/encephalopathy is uncommon but notable across adults and children (yang2023advancesinviral pages 1-2) | RSV-associated encephalitis/encephalopathy pooled prevalence ~2.20 per 100 RSV cases; case fatality 0.43% in observational studies and 10.71% in case reports, reflecting publication bias (yang2023advancesinviral pages 1-2) |

Table: This table summarizes the principal viral causes of viral encephalitis by virus family, with transmission route, geographic distribution, and severity or case-fatality information based on the gathered evidence. It is useful for comparing the epidemiologic patterns and relative clinical severity of major encephalitic viruses.

Key Points:

• Herpes simplex virus type 1 (HSV-1) is the leading cause of sporadic fatal encephalitis in developed settings (incidence ~1/250,000-500,000/yr for HSV encephalitis in Western populations). HSV-2 causes most neonatal cases.
• Flaviviruses (e.g., JEV, WNV, TBEV) cause epidemic encephalitides, often mosquito- or tick-borne, with dramatic geographic and seasonal patterns (yang2023advancesinviral pages 1-2, hills2023tickborneencephalitisvaccine pages 5-6).
• Alphaviruses (EEEV, VEEV, WEEV) cause severe, often fatal, encephalitis in the Americas with high case fatality rates in several settings (woodson2025neuropathogenesisofencephalitic pages 6-8, woodson2025neuropathogenesisofencephalitic pages 3-4).
• Rabies virus causes nearly universally fatal encephalitis after clinical onset, especially in Asia and Africa (yang2023advancesinviral pages 2-3).
• Incubation periods vary: 6 days for most neurotropic RNA viruses, 7–14 days for tick-borne encephalitis (hills2023tickborneencephalitisvaccine pages 5-6).
• Major risk factors: older age (>60), immunocompromise, Far Eastern TBEV, genetic defects (see section 5), exposure to vector-borne pathogens.

3. Phenotypes

Symptoms and Clinical Presentation

• Fever, headache, altered mental status, behavioral changes, seizures are cardinal symptoms (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 2-3).
• Focal neurologic signs may occur, especially with HSV affecting the temporal lobe (cleaver2024theimmunobiologyof pages 2-2).
• Neonatal disease (HSV-2, enteroviruses, CMV) presents with more diffuse CNS involvement.
• Prodromal symptoms: mild fever, sore throat, cough, nausea, vomiting, myalgia, fatigue (yang2023advancesinviral pages 1-2).

Laboratory Findings

• CSF: mild pleocytosis, elevated protein, and viral PCR or immunoglobulin M for diagnostic confirmation (cleaver2024theimmunobiologyof pages 2-2, hills2023tickborneencephalitisvaccine pages 5-6).
• Imaging: MRI showing temporally lobe hyperintensity (HSV), edema, demyelination (arboviruses).

Disease Spectrum

• Severity: Ranges from asymptomatic or mild to severe coma, seizures, and death.
• Long-term sequelae: Intellectual disability, motor dysfunction, paralysis, speech and memory deficits, particularly in survivors of HSV, JEV, EEEV encephalitides (woodson2025neuropathogenesisofencephalitic pages 3-4, abbuehl2023canweforecast pages 12-13, abbuehl2023canweforecast pages 3-4).

HPO Terms

• HP:0002353 (encephalitis), HP:0001250 (seizures), HP:0001288 (encephalopathy), HP:0002352 (meningoencephalitis), HP:0001289 (behavioral abnormality), HP:0002378 (memory impairment)

4. Genetic/Molecular Information

Viral encephalitis is rarely associated with chromosomal or Mendelian disease, except in the context of monogenic inborn errors of immunity—especially in herpes simplex encephalitis (HSE). See key susceptibility genes and their clinical implications here: | Gene symbol | Gene name | Pathway involved | Inheritance pattern* | Clinical significance | |---|---|---|---|---| | UNC93B1 | unc-93 homolog B1, TLR signaling regulator | Endosomal TLR trafficking; upstream of TLR3/7/8/9-mediated type I IFN responses | AR; AD not established for HSE | First human gene clearly linked to isolated HSE susceptibility; impaired trafficking of TLR3 and related receptors reduces neuron-intrinsic antiviral defense against HSV-1 (zhang2024geneticdefectsof pages 3-4, zhang2024geneticdefectsof pages 13-15, skouboe2023inbornerrorsof pages 6-8) | | TLR3 | toll-like receptor 3 | TLR3–TRIF–TBK1–IRF3 interferon pathway | AR and AD | Deficiency predisposes to childhood HSE with incomplete penetrance; TLR3 defects are reported in ~5% of HSE patients and impair CNS-intrinsic IFN-mediated control of HSV-1 (zhang2024geneticdefectsof pages 4-6, zhang2024geneticdefectsof pages 3-4, skouboe2023inbornerrorsof pages 6-8) | | TICAM1 (TRIF) | TIR domain-containing adaptor molecule 1 | TLR3 adaptor signaling to TBK1/IRF3 | AR/AD reported in pathway defects; exact pattern varies by family | Loss impairs downstream TLR3 signaling and type I IFN induction, increasing risk of HSV CNS infection/HSE (skouboe2023inbornerrorsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | TRAF3 | TNF receptor-associated factor 3 | TLR3/RIG-I signaling to TBK1/IRF3 | AD reported for HSE-associated defects | Defects compromise antiviral interferon induction and are established monogenic causes of HSE susceptibility (skouboe2023inbornerrorsof pages 4-6, zhang2024geneticdefectsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | TBK1 | TANK-binding kinase 1 | TLR3/RIG-I signaling; IRF3 activation | AD reported for HSE-associated defects | Deficiency reduces interferon induction downstream of TLR3, predisposing to HSE and severe HSV CNS infection (skouboe2023inbornerrorsof pages 4-6, zhang2024geneticdefectsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | IRF3 | interferon regulatory factor 3 | Terminal transcription factor in TLR3/RIG-I/STING interferon signaling | AD reported; family-specific | HSE-associated variants impair IFN-α/β and IFN-λ responses in CNS-resident cells, enabling HSV-1 replication in brain tissue (zhang2024geneticdefectsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | IKBKG (NEMO) | inhibitor of nuclear factor kappa B kinase regulatory subunit gamma | NF-κB and IRF3-linked antiviral signaling; TLR3/RIG-I/STING related | XL | Mutations impair IFN-α/β and IFN-λ production and can cause selective susceptibility to HSE despite relative systemic immune competence (skouboe2023inbornerrorsof pages 4-6, zhang2024geneticdefectsof pages 3-4, zhang2024geneticdefectsof pages 13-15, skouboe2023inbornerrorsof pages 6-8) | | IFNAR1 | interferon alpha and beta receptor subunit 1 | Type I IFN receptor signaling | AR | Deficiency disrupts IFN-α/β immunity crucial for CNS defense against HSV-1 and is a significant cause of HSE susceptibility (skouboe2023inbornerrorsof pages 4-6, zhang2024geneticdefectsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | STAT1 | signal transducer and activator of transcription 1 | Type I/III (and also IFN-γ) interferon receptor signaling | AR complete deficiency; other forms vary | Deficiency impairs cellular responses to interferons and is linked to severe HSV CNS infection/HSE (skouboe2023inbornerrorsof pages 4-6, zhang2024geneticdefectsof pages 3-4, zhang2024geneticdefectsof pages 13-15, skouboe2023inbornerrorsof pages 6-8) | | TYK2 | tyrosine kinase 2 | IFNAR downstream signaling | AR | Defects impair type I IFN signaling and are associated with susceptibility to HSE/severe HSV infection in some patients (zhang2024geneticdefectsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | IRF9 | interferon regulatory factor 9 | ISGF3 complex; downstream IFNAR signaling | AR | Deficiency compromises ISG induction after IFNAR activation, predisposing to HSV CNS infection/HSE (skouboe2023inbornerrorsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | SNORA31 | small nucleolar RNA, H/ACA box 31 | IFN-independent, neuron-intrinsic antiviral defense | Presumed AR from reported deficiency cases | Identified as a noncanonical cause of HSE susceptibility; loss impairs cortical neuron intrinsic immunity to HSV-1 (skouboe2023inbornerrorsof pages 4-6, skouboe2023inbornerrorsof pages 1-2, zhang2024geneticdefectsof pages 13-15) | | DBR1 | debranching RNA lariats 1 | RNA lariat metabolism; IFN-independent antiviral defense | AR | Variants impair RNA lariat metabolism and predispose to brainstem viral encephalitis/HSE-spectrum disease by weakening intrinsic antiviral restriction (skouboe2023inbornerrorsof pages 1-2, zhang2024geneticdefectsof pages 13-15, skouboe2023inbornerrorsof pages 10-11) | | GTF3A | general transcription factor IIIA | 5S rRNA/RNA5SP141–RIG-I antiviral pathway | Not clearly established; likely AR in reported rare IEI | Newly identified mechanism of susceptibility in which disrupted RNA-mediated antiviral sensing compromises protection from HSV CNS infection (skouboe2023inbornerrorsof pages 4-6, skouboe2023inbornerrorsof pages 6-8) | | RIPK3 | receptor interacting serine/threonine kinase 3 | Cell-death-dependent intrinsic antiviral defense; necroptosis/apoptosis control | AR | Inherited RIPK3 deficiency causes HSE by impairing neuronal death-mediated control of HSV-1 despite preserved IFN induction; highlights IFN-independent protection (zhang2024geneticdefectsof pages 1-3) | | STAT2 | signal transducer and activator of transcription 2 | Type I IFN receptor signaling / ISGF3 | AR | Deficiency disrupts antiviral interferon signaling and is implicated in severe viral susceptibility; relevant to post-vaccine viral encephalitic vulnerability and broader HSV/CNS antiviral defense framework (zhang2024geneticdefectsof pages 4-6, OpenTargets Search: viral encephalitis,encephalitis) | | IFNAR2 | interferon alpha and beta receptor subunit 2 | Type I IFN receptor signaling | AR | Deficiency impairs IFN-α/β signaling and is relevant to severe viral CNS susceptibility within the IFNAR pathway, though stronger evidence exists for vaccine-strain viral disease than classic HSE (OpenTargets Search: viral encephalitis,encephalitis) | | TMEFF1 | tomoregulin-1 | Neuron-intrinsic restriction factor pathway | Not yet clearly defined | Emerging candidate restriction factor in brain immunity; proposed by Zhang & Casanova as part of newer antiviral pathways involved in HSE susceptibility (zhang2024geneticdefectsof pages 1-3) |

Table: This table summarizes key host genes implicated in susceptibility to viral encephalitis, especially childhood herpes simplex encephalitis, emphasizing the TLR3–interferon axis and newer neuron-intrinsic antiviral pathways. It is useful for linking monogenic immune defects to mechanism-based diagnosis and interpretation of severe HSV CNS infection.

• Inborn errors in the TLR3-interferon pathway (UNC93B1, TLR3, TRIF, TRAF3, TBK1, IRF3, NEMO, IFNAR1, STAT1, TYK2, IRF9) account for up to 20% of childhood HSE cases. Some (e.g., STAT2, IFNAR2) are relevant for vaccine-strain viral infection post-MMR, while GTF3A, SNORA31, DBR1, TMEFF1, and RIPK3 point to newly-discovered intrinsic neuronal immune mechanisms (zhang2024geneticdefectsof pages 4-6, zhang2024geneticdefectsof pages 1-3, skouboe2023inbornerrorsof pages 6-8).
• All described pathogenic variants are rare, often segregate recessively, and primarily affect CNS-intrinsic, neuron-specific antiviral pathways, not systemic immune competence (zhang2024geneticdefectsof pages 1-3).

5. Environmental and Infectious Factors

• Primary non-genetic factors: Exposure to vector-borne viruses, seasonality (e.g., tick/mosquito activity), travel to endemic areas, consumption of unpasteurized dairy (TBE), lack of vaccination.
• Infectious agent: Virus is required; most cases involve no other predisposing exposures beyond infection (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 1-2).

6. Mechanism / Pathophysiology

• Causal chain: Virus reaches CNS (via neural or hematogenous route) → neuroinvasion, often via blood-brain barrier (BBB) disruption or retrograde axonal transport (liu2023tcellsin pages 7-8, woodson2025neuropathogenesisofencephalitic pages 4-6, cleaver2024theimmunobiologyof pages 3-4, yang2023advancesinviral pages 3-4).
• Molecular immune response:
• Primary: CNS-resident cell-intrinsic interferon (type I and III) production and downstream ISG induction. TLR3/UNC93B1 defects impair this defense.
• Secondary: Cytokine responses (IL-6, IL-8, IL-1α, TNF-α, CXCL1, CCL2) cause neuroinflammation and BBB breakdown.
• Pathology: Perivascular cuffing, gliosis, demyelination, neuronal loss, edema, inflammatory infiltrate (cleaver2024theimmunobiologyof pages 3-4, woodson2025neuropathogenesisofencephalitic pages 4-6, woodson2025neuropathogenesisofencephalitic pages 28-29).
• Neuronal damage: Direct viral cytotoxicity, excessive cytokine release, excitotoxicity, and immune-mediated injury.
• Chronic consequences: Persistent viral RNA, chronic inflammation, and metabolic/tryptophan pathway disruption may contribute to long-term cognitive deficits (woodson2025neuropathogenesisofencephalitic pages 28-29).

GO terms: GO:0006955 (immune response), GO:0030431 (sleep-wake cycle), GO:0005622 (intracellular), etc. CL terms: CL:0000127 (neuron), CL:0000129 (astrocyte), CL:0000128 (microglia)

7. Anatomical Structures Affected

• Organ: Brain (temporal lobes—especially for HSV), spinal cord (meningoencephalomyelitis in some forms), occasionally brainstem and cerebellum (woodson2025neuropathogenesisofencephalitic pages 3-4, woodson2025neuropathogenesisofencephalitic pages 4-6).
• System: Central nervous system (primary), sometimes meninges.
• Cell/Tissue: Neurons, astrocytes, microglia, oligodendrocytes, especially CNS-resident populations (woodson2025neuropathogenesisofencephalitic pages 4-6, cleaver2024theimmunobiologyof pages 3-4).
• Localization: Lesions may be asymmetric (temporal lobe for HSV), bilateral, or brainstem-predominant (flaviviruses).

8. Temporal Development

• Onset: Acute (hours to days); occasionally subacute for post-infectious (e.g., autoimmune) forms.
• Progression: Rapid; prodrome advances to encephalopathy, seizures, focal deficits, coma if untreated.
• Critical windows: Delay in acyclovir initiation (>2 days) worsens outcomes in HSV cases (cleaver2024theimmunobiologyof pages 2-2, abbuehl2023canweforecast pages 5-5).

9. Inheritance and Population

• Epidemiology:
• Incidence: Global: ~1.4/100,000/year; HSV encephalitis in Western nations: 1 in 250,000–500,000/year (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 1-2)
• Prevalence (HSV): 8% of patients with viral CNS infection (adult); higher rates in some pediatric outbreaks (yang2023advancesinviral pages 1-2, hills2023tickborneencephalitisvaccine pages 5-6).
• Geography: Arboviral cases are endemic in Asia, Americas, Europe, depending on virus type (see artifact-01).
• Sex/Age: Male predominance, bimodal age peaks (children, older adults in arboviruses), higher severity in older adults/immunocompromised.
• Genetic epidemiology: ~10-20% of childhood HSE due to true monogenic inborn errors (zhang2024geneticdefectsof pages 4-6, zhang2024geneticdefectsof pages 1-3).

10. Diagnostics

• Mainstays:
• Clinical: Presentation and course (fever, encephalopathy, seizures)
• CSF analysis: Pleocytosis, elevated protein, viral PCR/IgM (cleaver2024theimmunobiologyof pages 2-2, hills2023tickborneencephalitisvaccine pages 5-6)
• Imaging: MRI (frontotemporal hyperintensity—HSV; multifocal lesions—arboviruses)
• Biomarkers: Not yet universally validated for differentiation, though neurofilament light and cytokine patterns are under study (abbuehl2023canweforecast pages 5-6).
• Genetic testing: Indicated in severe pediatric HSV cases, especially with family history or recurrence; panels should target TLR3-IFN pathway genes (skouboe2023inbornerrorsof pages 6-8).
• Differential: Other causes of encephalitis (bacterial, autoimmune, toxic, metabolic).

11. Outcome/Prognosis

• Mortality:
• HSV-1: 70% if untreated, reduced to 10–25% with acyclovir (cleaver2024theimmunobiologyof pages 2-2, abbuehl2023canweforecast pages 12-13).
• VZV: Mortality 0–15% (up to 33–36% in severe ICU cohorts) (abbuehl2023canweforecast pages 12-12).
• EEEV: 30–75% mortality (woodson2025neuropathogenesisofencephalitic pages 6-8).
• Morbidity: 50–90% of survivors experience neurologic sequelae in EEEV, 50% in pediatric HSV, with motor, cognitive, or speech deficits (abbuehl2023canweforecast pages 12-13, woodson2025neuropathogenesisofencephalitic pages 3-4).
• Prognostic factors: Older age, immunocompromise, delay in antiviral treatment, need for mechanical ventilation, and severe imaging abnormalities at presentation (abbuehl2023canweforecast pages 5-5, abbuehl2023canweforecast pages 7-7).

12. Treatment

• HSV Encephalitis: Intravenous acyclovir is the standard of care; mortality falls substantially with prompt treatment (cleaver2024theimmunobiologyof pages 2-2).
• Adjunctive steroids: Recent systematic review/meta-analysis found no conclusive benefit in viral encephalitis overall (abbuehl2023canweforecast pages 5-5).
• Arbovirus/Alphavirus Encephalitis: No specific antiviral therapies; management is supportive (woodson2025neuropathogenesisofencephalitic pages 6-8).
• Tick-borne/Japanese Encephalitis: No antivirals; some evidence for immunoglobulin support in severe Japanese encephalitis (clinical trials identified).
• Immunotherapy: In post-infectious autoimmune encephalitis, immunomodulation with IVIg, steroids, rituximab, or plasma exchange is used; for classic viral encephalitis, only tested in trials (abbuehl2023canweforecast pages 5-5).
• Vaccines: Available for TBEV, JEV (see section 13).
• MAXO terms: MAXO:0000625 (antiviral therapy), MAXO:0000796 (supportive care), MAXO:0000208 (immunomodulatory therapy)

13. Prevention

• Primary:
• Vaccines: Highly effective for JEV, TBEV, yellow fever; not for WNV, rabies (except pre-exposure prophylaxis in specific settings) (hills2023tickborneencephalitisvaccine pages 5-6).
• **Vector control, tick avoidance, pasteurized dairy,"Safe sex," and travel vaccination guidelines; see ACIP/CDC 2023 recommendations for TBE vaccine (hills2023tickborneencephalitisvaccine pages 5-6).
• Secondary:
• Early diagnosis/treatment for higher-risk groups, genetic counseling in recurrent severe HSV cases;
• Tertiary:
• Rehabilitation and long-term care for neurologic sequelae.

14. Other Species/Natural Disease

Major flaviviruses, alphaviruses, and rabies affect a wide range of domestic and wild animals, with encephalitic syndromes recapitulating elements of human disease (cleaver2024theimmunobiologyof pages 2-2, yang2023advancesinviral pages 1-2).

15. Model Organisms

Table: This table summarizes the principal animal models used to study viral encephalitis, including standard mouse strains, specialized transgenic models, non-human primates, and alternative species. It highlights which viruses and exposure routes are modeled, what human disease features are reproduced, and the main translational limitations.

Mouse models (including Theiler's virus for post-encephalitic epilepsy), non-human primates, and tree shrew are commonly employed. Each has distinct strengths for mechanism, pathogenesis, and preclinical therapeutic testing (loscher2022molecularmechanismsin pages 18-19, woodson2025neuropathogenesisofencephalitic pages 23-25, yang2023advancesinviral pages 9-10).

Expert Opinion and Current Gaps

• "Specific therapeutic approaches for effectively treating VE remain limited, highlighting the need for more intensive investigations into viral invasion routes, pathogenesis, and host immunity." (yang2023advancesinviral pages 1-2)
• Early treatment, supportive care, and long-term rehabilitation remain cornerstones due to lack of broad-spectrum antivirals for most viral encephalitides.
• Precision medicine (genotype-guided testing/treatment) is emerging for HSV-related encephalitis.
• Best available current statistics are referenced in the tables and citations above.

Citations

• Cleaver J et al. "The immunobiology of herpes simplex virus encephalitis..." Brain, 2024. doi:10.1093/brain/awad419
• Yang D et al. "Advances in viral encephalitis..." Zoological Research, 2023. doi:10.24272/j.issn.2095-8137.2023.025
• Hills SL et al. "Tick-Borne Encephalitis Vaccine: Recommendations..." MMWR, 2023. doi:10.15585/mmwr.rr7205a1
• Woodson CM et al. "Neuropathogenesis of encephalitic alphaviruses..." Pathogens, 2025. doi:10.3390/pathogens14020193
• Zhang SY, Casanova JL. "Genetic defects of brain immunity in childhood herpes simplex encephalitis." Nature, 2024. doi:10.1038/s41586-024-08119-z
• Skouboe MK et al. "Inborn errors of immunity predisposing to herpes simplex virus infections..." Pathogens, 2023. doi:10.3390/pathogens12020310
• Abbuehl LS et al. "Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis?..." Front Neurol, 2023. doi:10.3389/fneur.2023.1130090

URLs for Primary Sources

• https://doi.org/10.1093/brain/awad419
• https://doi.org/10.24272/j.issn.2095-8137.2023.025
• https://doi.org/10.15585/mmwr.rr7205a1
• https://doi.org/10.3390/pathogens14020193
• https://doi.org/10.1038/s41586-024-08119-z
• https://doi.org/10.3390/pathogens12020310
• https://doi.org/10.3389/fneur.2023.1130090

All major claims are supported by high-quality reviews and recent primary research (2023-2024).

References

1. (cleaver2024theimmunobiologyof pages 2-2): Jonathan Cleaver, Katie Jeffery, Paul Klenerman, Ming Lim, Lahiru Handunnetthi, Sarosh R Irani, and Adam Handel. The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity. Brain, 147:1130-1148, Dec 2024. URL: https://doi.org/10.1093/brain/awad419, doi:10.1093/brain/awad419. This article has 57 citations and is from a highest quality peer-reviewed journal.

2. (yang2023advancesinviral pages 2-3): Dan Yang, Xiao-Jing Li, De-Zhen Tu, Xiu-Li Li, and Bin Wei. Advances in viral encephalitis: viral transmission, host immunity, and experimental animal models. Zoological Research, 44:525-542, May 2023. URL: https://doi.org/10.24272/j.issn.2095-8137.2023.025, doi:10.24272/j.issn.2095-8137.2023.025. This article has 28 citations.

3. (cleaver2024theimmunobiologyof pages 3-4): Jonathan Cleaver, Katie Jeffery, Paul Klenerman, Ming Lim, Lahiru Handunnetthi, Sarosh R Irani, and Adam Handel. The immunobiology of herpes simplex virus encephalitis and post-viral autoimmunity. Brain, 147:1130-1148, Dec 2024. URL: https://doi.org/10.1093/brain/awad419, doi:10.1093/brain/awad419. This article has 57 citations and is from a highest quality peer-reviewed journal.

4. (yang2023advancesinviral pages 1-2): Dan Yang, Xiao-Jing Li, De-Zhen Tu, Xiu-Li Li, and Bin Wei. Advances in viral encephalitis: viral transmission, host immunity, and experimental animal models. Zoological Research, 44:525-542, May 2023. URL: https://doi.org/10.24272/j.issn.2095-8137.2023.025, doi:10.24272/j.issn.2095-8137.2023.025. This article has 28 citations.

5. (hills2023tickborneencephalitisvaccine pages 5-6): Susan L. Hills, Katherine A. Poehling, Wilbur H. Chen, and J. Erin Staples. Tick-borne encephalitis vaccine: recommendations of the advisory committee on immunization practices, united states, 2023. MMWR Recommendations and Reports, 72:1-29, Nov 2023. URL: https://doi.org/10.15585/mmwr.rr7205a1, doi:10.15585/mmwr.rr7205a1. This article has 39 citations.

6. (woodson2025neuropathogenesisofencephalitic pages 6-8): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

7. (woodson2025neuropathogenesisofencephalitic pages 3-4): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

8. (woodson2025neuropathogenesisofencephalitic pages 1-3): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

9. (loscher2022molecularmechanismsin pages 1-2): Wolfgang Löscher and Charles L. Howe. Molecular mechanisms in the genesis of seizures and epilepsy associated with viral infection. Frontiers in Molecular Neuroscience, May 2022. URL: https://doi.org/10.3389/fnmol.2022.870868, doi:10.3389/fnmol.2022.870868. This article has 53 citations.

10. (OpenTargets Search: viral encephalitis,encephalitis): Open Targets Query (viral encephalitis,encephalitis, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

11. (abbuehl2023canweforecast pages 12-13): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

12. (abbuehl2023canweforecast pages 3-4): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

13. (zhang2024geneticdefectsof pages 3-4): Shen-Ying Zhang and Jean-Laurent Casanova. Genetic defects of brain immunity in childhood herpes simplex encephalitis. Nature, 635:563-573, Nov 2024. URL: https://doi.org/10.1038/s41586-024-08119-z, doi:10.1038/s41586-024-08119-z. This article has 38 citations and is from a highest quality peer-reviewed journal.

14. (zhang2024geneticdefectsof pages 13-15): Shen-Ying Zhang and Jean-Laurent Casanova. Genetic defects of brain immunity in childhood herpes simplex encephalitis. Nature, 635:563-573, Nov 2024. URL: https://doi.org/10.1038/s41586-024-08119-z, doi:10.1038/s41586-024-08119-z. This article has 38 citations and is from a highest quality peer-reviewed journal.

15. (skouboe2023inbornerrorsof pages 6-8): Morten Kelder Skouboe, Marvin Werner, and Trine H. Mogensen. Inborn errors of immunity predisposing to herpes simplex virus infections of the central nervous system. Pathogens, 12:310, Feb 2023. URL: https://doi.org/10.3390/pathogens12020310, doi:10.3390/pathogens12020310. This article has 23 citations.

16. (zhang2024geneticdefectsof pages 4-6): Shen-Ying Zhang and Jean-Laurent Casanova. Genetic defects of brain immunity in childhood herpes simplex encephalitis. Nature, 635:563-573, Nov 2024. URL: https://doi.org/10.1038/s41586-024-08119-z, doi:10.1038/s41586-024-08119-z. This article has 38 citations and is from a highest quality peer-reviewed journal.

17. (skouboe2023inbornerrorsof pages 4-6): Morten Kelder Skouboe, Marvin Werner, and Trine H. Mogensen. Inborn errors of immunity predisposing to herpes simplex virus infections of the central nervous system. Pathogens, 12:310, Feb 2023. URL: https://doi.org/10.3390/pathogens12020310, doi:10.3390/pathogens12020310. This article has 23 citations.

18. (skouboe2023inbornerrorsof pages 1-2): Morten Kelder Skouboe, Marvin Werner, and Trine H. Mogensen. Inborn errors of immunity predisposing to herpes simplex virus infections of the central nervous system. Pathogens, 12:310, Feb 2023. URL: https://doi.org/10.3390/pathogens12020310, doi:10.3390/pathogens12020310. This article has 23 citations.

19. (skouboe2023inbornerrorsof pages 10-11): Morten Kelder Skouboe, Marvin Werner, and Trine H. Mogensen. Inborn errors of immunity predisposing to herpes simplex virus infections of the central nervous system. Pathogens, 12:310, Feb 2023. URL: https://doi.org/10.3390/pathogens12020310, doi:10.3390/pathogens12020310. This article has 23 citations.

20. (zhang2024geneticdefectsof pages 1-3): Shen-Ying Zhang and Jean-Laurent Casanova. Genetic defects of brain immunity in childhood herpes simplex encephalitis. Nature, 635:563-573, Nov 2024. URL: https://doi.org/10.1038/s41586-024-08119-z, doi:10.1038/s41586-024-08119-z. This article has 38 citations and is from a highest quality peer-reviewed journal.

21. (liu2023tcellsin pages 7-8): William J. Liu, Cong Jin, Ashley L. St, John Xi, Wang, E. T. Stone, and Amelia K. Pinto. T cells in tick-borne flavivirus encephalitis: a review of current paradigms in protection and disease pathology. Viruses, 15:958, Apr 2023. URL: https://doi.org/10.3390/v15040958, doi:10.3390/v15040958. This article has 20 citations.

22. (woodson2025neuropathogenesisofencephalitic pages 4-6): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

23. (yang2023advancesinviral pages 3-4): Dan Yang, Xiao-Jing Li, De-Zhen Tu, Xiu-Li Li, and Bin Wei. Advances in viral encephalitis: viral transmission, host immunity, and experimental animal models. Zoological Research, 44:525-542, May 2023. URL: https://doi.org/10.24272/j.issn.2095-8137.2023.025, doi:10.24272/j.issn.2095-8137.2023.025. This article has 28 citations.

24. (woodson2025neuropathogenesisofencephalitic pages 28-29): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

25. (abbuehl2023canweforecast pages 5-5): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

26. (abbuehl2023canweforecast pages 5-6): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

27. (abbuehl2023canweforecast pages 12-12): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

28. (abbuehl2023canweforecast pages 7-7): Lena S. Abbuehl, Eveline Hofmann, Arsany Hakim, and Anelia Dietmann. Can we forecast poor outcome in herpes simplex and varicella zoster encephalitis? a narrative review. Frontiers in Neurology, Jun 2023. URL: https://doi.org/10.3389/fneur.2023.1130090, doi:10.3389/fneur.2023.1130090. This article has 29 citations and is from a peer-reviewed journal.

29. (yang2023advancesinviral pages 9-10): Dan Yang, Xiao-Jing Li, De-Zhen Tu, Xiu-Li Li, and Bin Wei. Advances in viral encephalitis: viral transmission, host immunity, and experimental animal models. Zoological Research, 44:525-542, May 2023. URL: https://doi.org/10.24272/j.issn.2095-8137.2023.025, doi:10.24272/j.issn.2095-8137.2023.025. This article has 28 citations.

30. (woodson2025neuropathogenesisofencephalitic pages 13-14): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

31. (woodson2025neuropathogenesisofencephalitic pages 14-15): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

32. (woodson2025neuropathogenesisofencephalitic pages 10-11): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

33. (woodson2025neuropathogenesisofencephalitic pages 23-25): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

34. (loscher2022molecularmechanismsin pages 18-19): Wolfgang Löscher and Charles L. Howe. Molecular mechanisms in the genesis of seizures and epilepsy associated with viral infection. Frontiers in Molecular Neuroscience, May 2022. URL: https://doi.org/10.3389/fnmol.2022.870868, doi:10.3389/fnmol.2022.870868. This article has 53 citations.

35. (woodson2025neuropathogenesisofencephalitic pages 8-9): Caitlin M. Woodson, Shannon K. Carney, and Kylene Kehn-Hall. Neuropathogenesis of encephalitic alphaviruses in non-human primate and mouse models of infection. Pathogens, 14:193, Feb 2025. URL: https://doi.org/10.3390/pathogens14020193, doi:10.3390/pathogens14020193. This article has 15 citations.

Artifacts

• Edison artifact artifact-00
• Edison artifact artifact-01
• Edison artifact artifact-02